About
About Pacific Biosciences of California, Inc
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Visit company website
5 years, 5 months ago
Pacific Biosciences of California, Inc is currently in a long term uptrend where the price is trading 17.4% above its 200 day moving average.
From a valuation standpoint, the stock is 94.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 74.5.
Pacific Biosciences of California, Inc's total revenue sank by 2.8% to $27M since the same quarter in the previous year.
Its net income has increased by 82446.2% to $75M since the same quarter in the previous year.
Finally, its free cash flow grew by 21.8% to $-14M since the same quarter in the previous year.
Based on the above factors, Pacific Biosciences of California, Inc gets an overall score of 4/5.